StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Sunday. The firm issued a sell rating on the stock.
Moleculin Biotech Price Performance
Shares of Moleculin Biotech stock opened at $2.58 on Friday. Moleculin Biotech has a 1 year low of $2.12 and a 1 year high of $15.75. The stock has a 50-day moving average price of $2.49 and a 200 day moving average price of $3.55.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, equities analysts forecast that Moleculin Biotech will post -8.6 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Moleculin Biotech
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- The How and Why of Investing in Gold Stocks
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Use the MarketBeat Stock Screener
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Are Some of the Best Large-Cap Stocks to Buy?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.